## Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

		Lugar i mig.			-011		1 Unit 4			
UNITED T Form 4 August 01, 1	HERAPEUTICS	Corp								
FORM	ЛΔ							OMB AF	PROVAL	
	UNITED		SECURITIES AND EXCHANGE CO Washington, D.C. 20549				OMMISSION	OMB Number:	3235-0287	
Check the check	iger STATEN	MENT OF CH					FRSHIP OF	Expires:	January 31, 2005	
subject Section Form 4	16.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Estimated average burden hours per response 0.5	
Form 5 obligation may corn See Inst 1(b).	ons ntinue. Section 17(	20(h) of the Inviectment (Commenty A of of $1040$ )								
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> DWEK RAYMOND			2. Issuer Name <b>and</b> Ticker or Trading Symbol UNITED THERAPEUTICS Corp [UTHR]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	ED THERAPEUT ATION, 1040 SPR	TICS 08/0	(Month/Day/Year) below 08/01/2013					below)		
			Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
SILVER S	PRING, MD 2091	10					Form filed by Mo Person			
(City)	(State)	(Zip)	Fable I - Non-F	Derivative	Secu	rities Acqu	ired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) ay/Year) (Instr. 8)			(D)	.) 5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)		
Common Stock	08/01/2013	08/01/2013	M <u>(1)</u>	3,000	А	\$ 27.7 ( <u>2)</u>	3,000	D		
Common Stock	08/01/2013	08/01/2013	S <u>(1)</u>	3,000	D	\$ 75.9377 ( <u>3)</u>	0	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control

### Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

#### number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number prof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	\$ 27.7 <u>(2)</u>	08/01/2013	08/01/2013	M <u>(1)</u>	3,000	06/26/2007	06/26/2016	Common Stock	3,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships					
r g the state of the state	Director	10% Owner	Officer	Other			
DWEK RAYMOND C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING, MD 20910	X X						
Signatures							
/s/ John S. Hess, Jr. under Power of Attorney	08/01/2013	3					
**Signature of Reporting Person	Date						
Explanation of Responses:							

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- (2) Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.

This transaction was executed in multiple trades at prices ranging from \$75.89 to \$76.07. The price reported above reflects the weighted (3) average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.